BOEHRINGER-INGELHEIM RECEIVES EU APPROVAL FOR HIV DRUG APTIVUS

Boehringer-Ingelheim GmbH said it has received approval from the European Commission to market its HIV drug Aptivus (tipravanir) for treatment of HIV in combination with other anti-retroviral agents. Aptivus specifically helps patients who have become resistant to current treatment options. Boehringer said authorisation was based on 'exceptional circumstances' given that HIV/AIDS is a life threatening illness with a need for rapid access to new treatment options.

Forbes (http://www.forbes.com/work/feeds/afx/2005/10/26/afx2299483.html)